Giant cell tumor of the distal ulna: a case report

Daniele Vanni¹, Andrea Pantalone¹, Elda Andreoli¹, Patrizio Caldora² and Vincenzo Salini¹*

Abstract

Introduction: Several cases of long bone giant cell tumor have been reported in the literature. We report the case of a patient with a giant cell tumor in the distal ulna. This is very unusual, with a reported incidence of 0.45 to 6%.

Case presentation: A 17-year-old Colombian man presented with a painful swelling of the left wrist. After performing an instrumental examination, a diagnosis of distal ulna giant cell tumor was made. The tumor was treated with an intralesional curettage, phenol application and bone grafting.

Conclusions: This tumor may have a good prognosis if it is diagnosed early and radically treated. It is important to be aware of atypical cancer localizations in order to perform a proper diagnosis.

Keywords: Adjuvant therapy, Curettage, GCT, Phenol, Ulna

Introduction

Bone giant cell tumor (GCT) is a rare, generally benign and locally aggressive tumor. It represents approximately 3% to 5% of all primary bone cancers. It generally occurs in adults between the ages of 20 and 40 years. GCT of bone is very rarely seen in children or in adults older than 65 years of age. GCT tumors occur in approximately one person per million per year. Usually, the tumor site is at the long bone meta-epiphysis, especially the distal radius and femur, proximal humerus and tibia. The ulna distal extremity is an unusual site (0.45% to 3.2%) for a primary bone GCT. We report the case of a distal ulna GCT diagnosed in a 17-year-old man. It was treated with intralesional curettage, adjuvant therapy with 5% phenol and a synthetic bone graft reconstruction.

Case presentation

A radiographic examination of the left wrist was performed in a 17-year-old Colombian man as a result of a direct incidental trauma. No fracture was seen, but an osteolytic area was found in the ulnar meta-epiphysis. The initial diagnosis was ‘juvenile bone cyst’. The patient presented with a painful swelling at the wrist dorsal ulnar side, about 2.5 cm, in the absence of any epidermal dyschromias. The skin was elastic and smooth. Wrist examination showed a range of motion (ROM) of 45° of extension, 70° of flexion, 15° of radial deviation and 10° of ulnar deviation; pronation, supination and circumduction were painful. Contralateral wrist ROM was normal. The diagnosis of ‘juvenile bone cyst’ did not seem right and a second radiographic examination was performed. At this time, a multilocular osteolytic area inducing an expansion of the distal ulna was seen. A cortical bone interruption was also visible. Although the patient had been the victim of a trauma, this was a poor prognostic sign. Therefore an Magnetic resonance imaging examination was performed. It showed a hypointense signal in the T1 sequences and a hyperintense signal in the short TI inversion recovery (STIR) sequences, characterized by enhancement after contrast administration, due to the presence of newly formed tissue (Figure 1).

After an incisional biopsy, the diagnosis of GCT was finally made, although it was in an atypical site.

The lesion was classified as a grade II with fracture (Figure 1), according to the Campanacci Classification and as a stage II according to the Enneking Classification for benign bone tumors (Figure 2).

Subsequently, the patient was surgically treated with intralesional curettage, adjuvant therapy with 5% phenol and a synthetic bone graft reconstruction.

A cortical bone rawplug was removed through a skin incision at the dorsomedial side of the deformity. Accessing the cystic cavity revealed a gelatinous ‘chocolate brown’ material, with many areas of darker color.
The cavity was carefully emptied and curetted (Figure 3), and then 5% phenol was applied in three cycles (Figure 4), with subsequent neutralization by hydrogen peroxide.

Then, using synthetic cancellous bone substitutes, a bone defect fill was performed (Figure 5) and the bone rawplug was synthesized using a cannulated screw (Figure 6, Figure 7).

A clinical and radiographic follow-up was performed one, three, six, 12, 24 and 48 months post-operatively to evaluate the bone consolidation. Chest radiographs were performed every six months. Within the first post-operative month, the patient completely recovered the wrist ROM. After 3 years, there have been no signs of recurrence.

**Discussion**

The bone GCT was first described in 1818 by Cooper and Travers. Its local aggression has been highlighted by Nelaton and its malignant potential by Virchow.

It is a rare tumor, essentially benign, but it may behave unexpectedly, regardless of the results of radiological or histological examinations.

It is usually located in the long bone meta-epiphysis and it frequently involves the subchondral bone without involvement of the articular surface; however, larger tumors may extend into the metaphysis and, more rarely, into the diaphysis. Proximal tibia, humerus, distal femur and radius are typical sites.

GCT represents about 3% to 5% of all bone tumors and 21% of benign bone tumors [1,2].
In 70% of cases, it involves women in the third to fourth decade of life.

The distal epiphysis of the ulna is an unusual place for a primary bone GCT; in fact, this occurs in only 0.45% to 3.2% of all primary bone GCT’s [3].

In the past, these tumors were treated with amputation or large resections and ulterior reconstructions. Currently, surgical treatments are:

- Intralesional curettage
- Curettage and bone grafting
- Cryotherapy of the cavity after curettage
- Application of phenol after curettage
- Radiation
- Insertion of methyl methacrylate cement in the cavity after curettage
- Resection followed by allograft
- En-bloc resection with or without reconstruction or stabilization of the ulna and prosthetic reconstruction
- Embolization of the feeding vessels

The variables related to the tumor, such as size, location, biological activity, cortical bone destruction or pathologic fracture evidence, determine the treatment [4].

Although an en-bloc resection radically assaults the tumor, significantly reducing the risk of recurrence, functional outcome is very bad. A simple curettage provides an excellent functional outcome, but with a higher recurrence rate of approximately 40% [1-5] if compared with the patients who received adjuvant therapy (45% versus 18%).

Therefore, various adjuvant therapies have been associated with the curettage: phenol, cryotherapy [6-8], cement or polymethyl methacrylate (PMMA) used intraoperatively.
The recurrence rate ranges from 5% to 8% when cement is used, and approximately 2.3% after cryosurgery [6,7].

However, it needs to be mentioned that a multicenter study of the Canadian Sarcoma Group [9] reported an overall recurrence rate of 17% and claimed that the filling material or the type of adjuvant would not have an absolute impact on recurrence.

Furthermore, some studies show that the use of an adjuvant would not be necessary in some cases, such as intraosseous GCT [10].

According to Schajowicz [11], curettage alone is an inadequate oncological procedure, but when it is combined with an adjuvant therapy, it globally provides a better result with respect to one-block excision, especially in terms of functionality.

Therefore, the correct treatment must achieve a balance between oncological radicality and the restoration of skeletal segment functionality [12-14].
Curettage associated with bone grafting has been shown to be effective in many cases [15]. In this study it is used with phenol as an adjuvant, because it is capable of causing protein and DNA coagulation, inducing cell necrosis.

In the present case intrasosional curettage was possible because the tumor was a grade II and the reconstruction was carried out with synthetic cancellous bone, due to the young age of the patient.

Conclusions
Neoinformation bone diagnosis is difficult and requires a great deal of experience, especially in young patients. Osteolytic lesions incidentally found at a long bone epiphysis, can be misinterpreted. This tumor may have a good prognosis if treated early and radically. It is important to know atypical cancer locations in order to perform a proper diagnosis.

Consent
Written informed consent was obtained from the patient’s next-of-kin for publication of this case report and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1Orthopedic and Traumatologic Division, “G. d’Annunzio” University, Via dei Vestini 35, 66013, Chieti, Italy. 2Orthopedic and Traumatologic Division, “S. Margherita” Hospital, Via N.A. Fratta 145, 52040, Cortona, Arezzo, Italy.

Authors’ contributions
DV was a major contributor in writing the manuscript and was involved in the bibliographic research. AP was involved in the bibliographic research and was also a major contributor in writing the manuscript. EA performed the surgery and was involved in the bibliographic research. PC performed the surgery and contributed in writing the manuscript. VS also performed the surgery and was involved in the bibliographic research. AP was involved in the bibliographic research. DV was a major contributor in writing the manuscript and was involved in the bibliographic research.

Received: 29 November 2011 Accepted: 1 June 2012
Published: 1 June 2012

References
1. Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K: The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004). Rare Tumors 2009, 1:152.
2. Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am 1987, 69:105–114.
3. Goldenberg RR, Campbell CJ, Bonfiglio M: Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am 1970, 52:619–664.
4. Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM: Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 1982, 64:755–761.
5. Masui F, Ushigome S, Fujii K: Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int 1998, 48:723–729.
6. Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y: Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res 1999, 359:176–188.
7. Malawer MM, Marks MR, McClure D, Piaio M, Gunther SF, Schmookler BV: The effect of cryosurgery and polymethyl methacrylate in dogs with experimental bone defects comparable to tumor defects. Clin Orthop Relat Res 1988, 226:299–310.
8. Marcove RC, Weis LD, Vaghaiwala MR, Pearson R, Huvos AG: Cryosurgery in the treatment of giant cell tumors of bone. A report of 52 consecutive cases. Cancer 1978, 41:957–969.
9. Turcotte RE, Wunder JS, Idler MH, Bell RS, Schachar N, Nasi BA, Moreau G, Davis AM, Canadian Sarcoma Group: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002, 397:248–258.
10. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ: Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 2005, 435:211–218.
11. Schajowicz F: Tumors and Tumor-like Lesions of Bone: Pathology, Radiology and Treatment; Springer-Verlag, 1994. ISBN 2nd.
12. Gracia I, Proubasta IR, Trullolès L, Peiró A, Moya E, Cortés S, Buezo O, Majó J: Distal radioulnar joint prosthesis for the treatment of giant cell tumor of the distal ulna: a case report and literature review. Strategies Trauma Limb Reconstr 2011, 6:103–106.
13. Singh M, Sharma S, Peshin C, Wani IH, Tikoo A, Gupta SK, Singh D: Wide resection and stabilization of ulnar stump by extensor carpi ulnaris for giant cell tumor of distal ulna: two case reports. Cases J 2009, 2:8617.
14. Burke CS, Gupta A, Buecker P: Distal ulna giant cell tumor resection with reconstruction using distal ulna prosthesis and brachioradialis wrap soft tissue stabilization. Hand (N Y) 2009, 4:410–414.
15. Ward WG Jr, Li G: Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res 2002, 397:259–270.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit